Generics Global Industry Almanac 2015-2024
Summary
Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The market value is evaluated at ex-factory prices.
- 麻豆原创 volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
- Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.
- Note that any volumes of "1" (one) or 100% are due to rounding as 麻豆原创Line does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.
- All currency conversions were calculated at constant average annual 2019 exchange rates.
- Figures presented in this report are calculated applying the "middle path" scenario - this is based on the current situation in countries where the epidemic burst first, like China as a model countries and the announcements made by governments, stating that the abnormal situation may last up to six months.
- The assumption has been made that after this time the economy will gradually go back to the levels recorded before the pandemics by the end of the year. It is also assumed that there is no widespread economic crisis as seen back in 2008 due to announced pay-outs across countries.
- At the moment of preparation of this report in July 2020 the economic implications of the lock downs of many economics are still very difficult to predict as there is no indication how long the pandemics could last, the number of sectors forced to stay closed and the scale of the governmental' aid involved.
- The global generics market had total revenues of $339.2bn in 2019, representing a compound annual growth rate (CAGR) of 6.1% between 2015 and 2019.
- 麻豆原创 consumption volume increased with a CAGR of 2.4% between 2015 and 2019, to reach a total of 54.6% in 2019.
- Asia-Pacific accounts for 38.3% of the global market value whilst Europe and the US make up 22.1% and 32.1% respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the global generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
- Leading company profiles reveal details of key generics market players鈥� global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume
Reasons to Buy
- What was the size of the global generics market by value in 2019?
- What will be the size of the global generics market in 2024?
- What factors are affecting the strength of competition in the global generics market?
- How has the market performed over the last five years?
- How large is the global generics market in relation to its regional counterparts?
Table of Contents
1 EXECUTIVE SUMMARY
1.1. 麻豆原创 value
1.2. 麻豆原创 value forecast
1.3. 麻豆原创 volume
1.4. 麻豆原创 volume forecast
1.5. Geography segmentation
1.6. Competitive Landscape
2 Introduction
2.1. What is this report about?
2.2. Who is the target reader?
2.3. How to use this report
2.4. Definitions
3 Global Generics
3.1. 麻豆原创 Overview
3.2. 麻豆原创 Data
3.3. 麻豆原创 Segmentation
3.4. 麻豆原创 outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
4 Generics in Asia-Pacific
4.1. 麻豆原创 Overview
4.2. 麻豆原创 Data
4.3. 麻豆原创 Segmentation
4.4. 麻豆原创 outlook
4.5. Five forces analysis
5 Generics in Europe
5.1. 麻豆原创 Overview
5.2. 麻豆原创 Data
5.3. 麻豆原创 Segmentation
5.4. 麻豆原创 outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
6 Generics in France
6.1. 麻豆原创 Overview
6.2. 麻豆原创 Data
6.3. 麻豆原创 Segmentation
6.4. 麻豆原创 outlook
6.5. Five forces analysis
6.6. Macroeconomic Indicators
7 Generics in Germany
7.1. 麻豆原创 Overview
7.2. 麻豆原创 Data
7.3. 麻豆原创 Segmentation
7.4. 麻豆原创 outlook
7.5. Five forces analysis
7.6. Macroeconomic Indicators
8 Generics in Australia
8.1. 麻豆原创 Overview
8.2. 麻豆原创 Data
8.3. 麻豆原创 Segmentation
8.4. 麻豆原创 outlook
8.5. Five forces analysis
8.6. Macroeconomic Indicators
9 Generics in Brazil
9.1. 麻豆原创 Overview
9.2. 麻豆原创 Data
9.3. 麻豆原创 Segmentation
9.4. 麻豆原创 outlook
9.5. Five forces analysis
9.6. Macroeconomic Indicators
10 Generics in Canada
10.1. 麻豆原创 Overview
10.2. 麻豆原创 Data
10.3. 麻豆原创 Segmentation
10.4. 麻豆原创 outlook
10.5. Five forces analysis
10.6. Macroeconomic Indicators
11 Generics in China
11.1. 麻豆原创 Overview
11.2. 麻豆原创 Data
11.3. 麻豆原创 Segmentation
11.4. 麻豆原创 outlook
11.5. Five forces analysis
11.6. Macroeconomic Indicators
12 Generics in India
12.1. 麻豆原创 Overview
12.2. 麻豆原创 Data
12.3. 麻豆原创 Segmentation
12.4. 麻豆原创 outlook
12.5. Five forces analysis
12.6. Macroeconomic Indicators
13 Generics in Indonesia
13.1. 麻豆原创 Overview
13.2. 麻豆原创 Data
13.3. 麻豆原创 Segmentation
13.4. 麻豆原创 outlook
13.5. Five forces analysis
13.6. Macroeconomic Indicators
14 Generics in Italy
14.1. 麻豆原创 Overview
14.2. 麻豆原创 Data
14.3. 麻豆原创 Segmentation
14.4. 麻豆原创 outlook
14.5. Five forces analysis
14.6. Macroeconomic Indicators
15 Generics in Japan
15.1. 麻豆原创 Overview
15.2. 麻豆原创 Data
15.3. 麻豆原创 Segmentation
15.4. 麻豆原创 outlook
15.5. Five forces analysis
15.6. Macroeconomic Indicators
16 Generics in Mexico
16.1. 麻豆原创 Overview
16.2. 麻豆原创 Data
16.3. 麻豆原创 Segmentation
16.4. 麻豆原创 outlook
16.5. Five forces analysis
16.6. Macroeconomic Indicators
17 Generics in The Netherlands
17.1. 麻豆原创 Overview
17.2. 麻豆原创 Data
17.3. 麻豆原创 Segmentation
17.4. 麻豆原创 outlook
17.5. Five forces analysis
17.6. Macroeconomic Indicators
18 Generics in North America
18.1. 麻豆原创 Overview
18.2. 麻豆原创 Data
18.3. 麻豆原创 Segmentation
18.4. 麻豆原创 outlook
18.5. Five forces analysis
19 Generics in Russia
19.1. 麻豆原创 Overview
19.2. 麻豆原创 Data
19.3. 麻豆原创 Segmentation
19.4. 麻豆原创 outlook
19.5. Five forces analysis
19.6. Macroeconomic Indicators
20 Generics in Scandinavia
20.1. 麻豆原创 Overview
20.2. 麻豆原创 Data
20.3. 麻豆原创 Segmentation
20.4. 麻豆原创 outlook
20.5. Five forces analysis
21 Generics in Singapore
21.1. 麻豆原创 Overview
21.2. 麻豆原创 Data
21.3. 麻豆原创 Segmentation
21.4. 麻豆原创 outlook
21.5. Five forces analysis
21.6. Macroeconomic Indicators
22 Generics in South Africa
22.1. 麻豆原创 Overview
22.2. 麻豆原创 Data
22.3. 麻豆原创 Segmentation
22.4. 麻豆原创 outlook
22.5. Five forces analysis
22.6. Macroeconomic Indicators
23 Generics in South Korea
23.1. 麻豆原创 Overview
23.2. 麻豆原创 Data
23.3. 麻豆原创 Segmentation
23.4. 麻豆原创 outlook
23.5. Five forces analysis
23.6. Macroeconomic Indicators
24 Generics in Spain
24.1. 麻豆原创 Overview
24.2. 麻豆原创 Data
24.3. 麻豆原创 Segmentation
24.4. 麻豆原创 outlook
24.5. Five forces analysis
24.6. Macroeconomic Indicators
25 Generics in Turkey
25.1. 麻豆原创 Overview
25.2. 麻豆原创 Data
25.3. 麻豆原创 Segmentation
25.4. 麻豆原创 outlook
25.5. Five forces analysis
25.6. Macroeconomic Indicators
26 Generics in The United Kingdom
26.1. 麻豆原创 Overview
26.2. 麻豆原创 Data
26.3. 麻豆原创 Segmentation
26.4. 麻豆原创 outlook
26.5. Five forces analysis
26.6. Macroeconomic Indicators
27 Generics in The United States
27.1. 麻豆原创 Overview
27.2. 麻豆原创 Data
27.3. 麻豆原创 Segmentation
27.4. 麻豆原创 outlook
27.5. Five forces analysis
27.6. Macroeconomic Indicators
28 Company Profiles
28.1. Teva Pharmaceutical Industries Limited
28.2. Pfizer Inc.
28.3. Sun Pharmaceutical Industries Ltd
28.4. Mylan N.V.
28.5. Sanofi SA
28.6. Les Laboratoires Servier
28.7. STADA Arzneimittel AG
28.8. Lupin Ltd
28.9. EMS SA
28.10. Ache Laboratorios Farmaceuticos SA
28.11. Eurofarma Laboratorios SA
28.12. Apotex, Inc.
28.13. China Grand Pharmaceutical and Healthcare Holdings Limited
28.14. Aurobindo Pharma Ltd
28.15. Cipla Limited
28.16. PT Kalbe Farma Tbk
28.17. PT Sanbe Farma
28.18. SOHO Global Health
28.19. PT Indofarma (Persero), Tbk
28.20. Daiichi Sankyo Co Ltd
28.21. Sawai Pharmaceutical Co Ltd
28.22. Krka, d. d., Novo mesto
28.23. Abbott Laboratories
28.24. Aspen Pharmacare Holdings Ltd
28.25. Adcock Ingram Holdings Ltd
28.26. Yuhan Corp
28.27. Esteve Group
28.28. Deva Holding AS
28.29. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
28.30. Nobelpharma Co Ltd
29 Appendix
29.1. Methodology
29.2. About 麻豆原创Line
List of Tables
List of Tables
Table 1: Global generics market value: $ billion, 2015鈥�19
Table 2: Global generics market volume: % of total pharma, 2015鈥�19
Table 3: Global generics market geography segmentation: $ billion, 2019
Table 4: Global generics market value forecast: $ billion, 2019鈥�24
Table 5: Global generics market volume forecast: % of total pharma, 2019鈥�24
Table 6: Global size of population (million), 2015鈥�19
Table 7: Global gdp (constant 2005 prices, $ billion), 2015鈥�19
Table 8: Global gdp (current prices, $ billion), 2015鈥�19
Table 9: Global inflation, 2015鈥�19
Table 10: Global consumer price index (absolute), 2015鈥�19
Table 11: Global exchange rate, 2015鈥�19
Table 12: Asia-Pacific generics market value: $ billion, 2015鈥�19
Table 13: Asia鈥揚acific generics market volume: % of total pharma, 2015鈥�19
Table 14: Asia鈥揚acific generics market geography segmentation: $ billion, 2019
Table 15: Asia-Pacific generics market value forecast: $ billion, 2019鈥�24
Table 16: Asia鈥揚acific generics market volume forecast: % of total pharma, 2019鈥�24
Table 17: Europe generics market value: $ billion, 2015鈥�19
Table 18: Europe generics market volume: % of total pharma, 2015鈥�19
Table 19: Europe generics market geography segmentation: $ billion, 2019
Table 20: Europe generics market value forecast: $ billion, 2019鈥�24
Table 21: Europe generics market volume forecast: % of total pharma, 2019鈥�24
Table 22: Europe size of population (million), 2015鈥�19
Table 23: Europe gdp (constant 2005 prices, $ billion), 2015鈥�19
Table 24: Europe gdp (current prices, $ billion), 2015鈥�19
Table 25: Europe inflation, 2015鈥�19
Table 26: Europe consumer price index (absolute), 2015鈥�19
Table 27: Europe exchange rate, 2015鈥�19
Table 28: France generics market value: $ million, 2015鈥�19
Table 29: France generics market volume: % of total pharma, 2015鈥�19
Table 30: France generics market geography segmentation: $ million, 2019
Table 31: France generics market value forecast: $ million, 2019鈥�24
Table 32: France generics market volume forecast: % of total pharma, 2019鈥�24
Table 33: France size of population (million), 2015鈥�19
Table 34: France gdp (constant 2005 prices, $ billion), 2015鈥�19
Table 35: France gdp (current prices, $ billion), 2015鈥�19
Table 36: France inflation, 2015鈥�19
Table 37: France consumer price index (absolute), 2015鈥�19
Table 38: France exchange rate, 2015鈥�19
Table 39: Germany generics market value: $ billion, 2015鈥�19
Table 40: Germany generics market volume: % of total pharma, 2015鈥�19
Table 41: Germany generics market geography segmentation: $ billion, 2019
Table 42: Germany generics market value forecast: $ billion, 2019鈥�24
Table 43: Germany generics market volume forecast: % of total pharma, 2019鈥�24
Table 44: Germany size of population (million), 2015鈥�19
Table 45: Germany gdp (constant 2005 prices, $ billion), 2015鈥�19
Table 46: Germany gdp (current prices, $ billion), 2015鈥�19
Table 47: Germany inflation, 2015鈥�19
Table 48: Germany consumer price index (absolute), 2015鈥�19
Table 49: Germany exchange rate, 2015鈥�19
Table 50: Australia generics market value: $ million, 2015鈥�19
List of Figures
List of Figures
Figure 1: Global generics market value: $ billion, 2015鈥�19
Figure 2: Global generics market volume: % of total pharma, 2015鈥�19
Figure 3: Global generics market geography segmentation: % share, by value, 2019
Figure 4: Global generics market value forecast: $ billion, 2019鈥�24
Figure 5: Global generics market volume forecast: % of total pharma, 2019鈥�24
Figure 6: Forces driving competition in the global generics market, 2019
Figure 7: Drivers of buyer power in the global generics market, 2019
Figure 8: Drivers of supplier power in the global generics market, 2019
Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2019
Figure 10: Factors influencing the threat of substitutes in the global generics market, 2019
Figure 11: Drivers of degree of rivalry in the global generics market, 2019
Figure 12: Asia-Pacific generics market value: $ billion, 2015鈥�19
Figure 13: Asia鈥揚acific generics market volume: % of total pharma, 2015鈥�19
Figure 14: Asia鈥揚acific generics market geography segmentation: % share, by value, 2019
Figure 15: Asia-Pacific generics market value forecast: $ billion, 2019鈥�24
Figure 16: Asia鈥揚acific generics market volume forecast: % of total pharma, 2019鈥�24
Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2019
Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2019
Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2019
Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2019
Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2019
Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2019
Figure 23: Europe generics market value: $ billion, 2015鈥�19
Figure 24: Europe generics market volume: % of total pharma, 2015鈥�19
Figure 25: Europe generics market geography segmentation: % share, by value, 2019
Figure 26: Europe generics market value forecast: $ billion, 2019鈥�24
Figure 27: Europe generics market volume forecast: % of total pharma, 2019鈥�24
Figure 28: Forces driving competition in the generics market in Europe, 2019
Figure 29: Drivers of buyer power in the generics market in Europe, 2019
Figure 30: Drivers of supplier power in the generics market in Europe, 2019
Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2019
Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2019
Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2019
Figure 34: France generics market value: $ million, 2015鈥�19
Figure 35: France generics market volume: % of total pharma, 2015鈥�19
Figure 36: France generics market geography segmentation: % share, by value, 2019
Figure 37: France generics market value forecast: $ million, 2019鈥�24
Figure 38: France generics market volume forecast: % of total pharma, 2019鈥�24
Figure 39: Forces driving competition in the generics market in France, 2019
Figure 40: Drivers of buyer power in the generics market in France, 2019
Figure 41: Drivers of supplier power in the generics market in France, 2019
Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2019
Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2019
Figure 44: Drivers of degree of rivalry in the generics market in France, 2019
Figure 45: Germany generics market value: $ billion, 2015鈥�19
Figure 46: Germany generics market volume: % of total pharma, 2015鈥�19
Figure 47: Germany generics market geography segmentation: % share, by value, 2019
Figure 48: Germany generics market value forecast: $ billion, 2019鈥�24
Figure 49: Germany generics market volume forecast: % of total pharma, 2019鈥�24
Figure 50: Forces driving competition in the generics market in Germany, 2019
Teva Pharmaceutical Industries Limited
Pfizer Inc.
Sun Pharmaceutical Industries Ltd
Mylan N.V.
Sanofi SA
Les Laboratoires Servier
STADA Arzneimittel AG
Lupin Ltd
EMS SA
Ache Laboratorios Farmaceuticos SA
Eurofarma Laboratorios SA
Apotex, Inc.
China Grand Pharmaceutical and Healthcare Holdings Limited
Aurobindo Pharma Ltd
Cipla Limited
PT Kalbe Farma Tbk
PT Sanbe Farma
SOHO Global Health
PT Indofarma (Persero), Tbk
Daiichi Sankyo Co Ltd
Sawai Pharmaceutical Co Ltd
Krka, d. d., Novo mesto
Abbott Laboratories
Aspen Pharmacare Holdings Ltd
Adcock Ingram Holdings Ltd
Yuhan Corp
Esteve Group
Deva Holding AS
Abdi Ibrahim Ilac Sanayi ve Ticaret AS
Nobelpharma Co Ltd
听
听
*If Applicable.